Spain Pharmaceuticals and Healthcare Report Q2 2014

Business Monitor International
March 26, 2014
101 Pages - SKU: BMI5222040
Countries covered: Spain

Spain Pharmaceuticals and Healthcare Report Q2 2014

BMI View: Despite the Spanish economy returning to growth in 2014, the country's pharmaceuticals andhealthcare sectors show no sign of following suit. The Spanish government's ongoing cash flow troublesand aggressive fiscal austerity measures, which focus heavily on cost containment in the healthcare sector,will continue to negatively impact pharmaceutical companies operating in Spain.

Headline Expenditure Projections

Pharmaceuticals: EUR24.09bn (US$31.79bn) in 2013 to EUR22.81bn (US$28.97bn) in 2014; -5.3% inlocal currency terms and -8.9% in US dollar terms.

Healthcare: EUR98.71bn (US$130.30bn) in 2013 to EUR98.57bn (US$125.19bn) in 2014; -0.1% inlocal currency terms and -3.9% in US dollar terms.



More Prescription Drugs reports by Business Monitor International

Taiwan Pharmaceuticals and Healthcare Report Q1 2015 by Business Monitor International
Taiwan Pharmaceuticals and Healthcare Report Q1 2015BMI View: Taiwan is one of the most attractive and stable prospects in the region for pharmaceutical andhealthcare investment, ...
Switzerland Pharmaceuticals and Healthcare Report Q1 2015 by Business Monitor International
Switzerland Pharmaceuticals and Healthcare Report Q1 2015BMI View: The Swiss government will need to develop policies to maintain the country's long-termattractiveness as a site for ...
Sudan Pharmaceuticals and Healthcare Report Q1 2015 by Business Monitor International
Sudan Pharmaceuticals and Healthcare Report Q1 2015BMI View: The already depreciating Sudanese pound will come under further strain should oil pricescontinue their decline as oil ...
Saudi Arabia Pharmaceuticals and Healthcare Report Q1 2015 by Business Monitor International
Saudi Arabia Pharmaceuticals and Healthcare Report Q1 2015BMI View: We expect heavy investment into Saudi Arabia's healthcare sector to continue, particularly asthe government sees the ...
See all reports like this >>

More Spain Prescription Drugs reports

Vancomycin: 2013-2018 Test Volume and Sales Forecasts by Country and Market Segment: Hospitals, Commercial Labs, POC Locations - France, Germany, Italy, Japan, Spain, UK, USA by VPGMarketResearch.com
This new report from VPGMarketResearch.com provides analysis of Vancomycin testing, including clinical significance, current and emerging diagnostic procedures, as well as test volume and sales ...
Valproic Acid: 2013-2018 Test Volume and Sales Forecasts by Country and Market Segment: Hospitals, Commercial Labs, POC Locations - France, Germany, Italy, Japan, Spain, UK, USA by VPGMarketResearch.com
This new report from VPGMarketResearch.com provides analysis of Valproic Acid testing, including clinical significance, current and emerging diagnostic procedures, as well as test volume and ...
Topirimate: 2013-2018 Test Volume and Sales Forecasts by Country and Market Segment: Hospitals, Commercial Labs, POC Locations - France, Germany, Italy, Japan, Spain, UK, USA by VPGMarketResearch.com
This new report from VPGMarketResearch.com provides analysis of Topirimate testing, including clinical significance, current and emerging diagnostic procedures, as well as test volume and sales ...
Tobramycin: 2013-2018 Test Volume and Sales Forecasts by Country and Market Segment: Hospitals, Commercial Labs, POC Locations - France, Germany, Italy, Japan, Spain, UK, USA by VPGMarketResearch.com
This new report from VPGMarketResearch.com provides analysis of Tobramycin testing, including clinical significance, current and emerging diagnostic procedures, as well as test volume and sales ...
See all reports like this >>

 

SELECT A LICENSE

    Report with 3 quarterly updates  USD 1,295  
    Report with 3 quarterly updates
3 User License
  USD 1,945  
    Report with 3 quarterly updates
5 User License
  USD 2,500  
    Report with 3 quarterly updates
Departmental/Site License
  USD 2,995  
    Global Site License Fulfilled by Publisher  USD 6,995  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!